<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819737</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00269; ko21Parmar</org_study_id>
    <nct_id>NCT04819737</nct_id>
  </id_info>
  <brief_title>Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences</brief_title>
  <official_title>Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Freie Akademische Gesellschaft Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged&#xD;
      magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis&#xD;
      (MS) lesion detection and to evaluate the additional clinical value of this sequence in&#xD;
      clinical settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An averaged magnetization inversion recovery acquisitions (AMIRA) sequence was proposed for&#xD;
      SC MRI. This MR-sequence delivers excellent contrast between the SC gray and white matter as&#xD;
      well as between the SC and cerebrospinal fluid (CSF) in clinically feasible-acquisition&#xD;
      times. Moreover, the high quality and in-plane resolution of AMIRA images allows for&#xD;
      segmentation of the SC gray and white matter with high accuracy and reproducibility. This&#xD;
      study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged&#xD;
      magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis&#xD;
      (MS) lesion detection and to evaluate the additional clinical value of this sequence in&#xD;
      clinical settings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants (embedded within the currently ongoing Swiss MS Cohort (SMSC) study) will undergo a single visit including a clinical interview, neurological examination and MRI.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of SC lesions</measure>
    <time_frame>one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time)</time_frame>
    <description>Number of SC lesions using AMIRA compared to gold-standard conventional SC MRI sequences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inter-observer agreement on SC lesion count</measure>
    <time_frame>one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time)</time_frame>
    <description>Inter-observer agreement with regard to lesion detection using AMIRA compared to gold-standard conventional SC MRI sequences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of ongoing inflammation (acute or chronic) in the SC</measure>
    <time_frame>one time assessment (60 minutes scheduled per patient for the MRI part including preparation time outside of the scanner and actual scanning time)</time_frame>
    <description>Presence of ongoing inflammation (acute or chronic) in the SC 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>Spinal Cord MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SC MRI</intervention_name>
    <description>SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.</description>
    <arm_group_label>Spinal Cord MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient questionnaire</intervention_name>
    <description>12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability</description>
    <arm_group_label>Spinal Cord MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple sclerosis according to established international criteria&#xD;
&#xD;
          -  Steroid free period: &gt; 4 weeks&#xD;
&#xD;
          -  Participation in the Swiss MS Cohort (SMSC) study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  . History of severe (other) neurological, internal or psychiatric disease with SC&#xD;
             affection&#xD;
&#xD;
          -  MRI-related exclusion criteria (questionnaire):&#xD;
&#xD;
               1. Paramagnetic and/or superparamagnetic foreign objects in the body (especially&#xD;
                  when located close to the SC)&#xD;
&#xD;
               2. Pacemaker&#xD;
&#xD;
               3. Claustrophobia&#xD;
&#xD;
               4. Pregnancy, lactation&#xD;
&#xD;
               5. Known hypersensitivity to gadolinium-based contrast media&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrin Parmar, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrin Parmar, PD Dr. med.</last_name>
    <phone>+41 61 83 65 214</phone>
    <email>katrin.parmar@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charidimos Tsagkas, Dr. med.</last_name>
    <email>charidimos.tsagkas@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Neurology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Katrin Parmar, PD Dr. med.</last_name>
      <email>katrin.parmar@unibas.ch</email>
    </contact>
    <investigator>
      <last_name>Katrin Parmar, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charidimos Tsagkas, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord (SC) pathology</keyword>
  <keyword>demyelinating lesions</keyword>
  <keyword>Spinal cord MRI</keyword>
  <keyword>Averaged magnetization inversion recovery acquisitions (AMIRA) sequence</keyword>
  <keyword>Swiss MS Cohort (SMSC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

